Patent SG-11201908672W-A (SG)
Title: Compositions and methods for treating synucleinopathies
Inventor: PENNER NATASHA
IPC: A61K39/395
Filed: 2018-03-30
Abstract: 1 5 60 C c3) 20 I- EC9O (2.1 nM Low (EC50 0.25nM) 40 0 0.0001 0.001 0.01 0.1 1 10 100 Dose response ran 100 igh - >EC90, target binding plateau (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT °mono n o oloinoin loolioluo VII IE (10) International Publication Number WO 2018/178950 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 25/00 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/IB2018/052236 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,818 31 March 2017 (31.03.2017) US 62/528,790 05 July 2017 (05.07.2017) US (71) Applicant: BIOGEN INTERNATIONAL NEU- ROSCIENCE GMBH [CH/CH]; Landis + Gyr-Strasse 3, 6300 Zug (CH). (72) Inventors: PENNER, Natasha; 23 Tanglewood Rd., New- ton, Massachusetts 02459 (US). MURALIDHARAN, Ku- mar Kandadi; 235 Arboretum Way, Burlington, Massa- chusetts 01803 (US). (74) Agent: CONROY, John, F.; Fish & Richardson P.C., Highlight Business Towers, Mies-van-der-Rohe-Strasse 8, D-80807 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) (54) Title: COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES FIGURE 5 6116054 Concentration in ISF(nM) (57) : Dosage regimens of anti-a-synuclein antibodies are provided. These dosage regimens find use in the treatment of synucleinopathies such as Parkinson's disease (PD), Parkinson's Disease Dementia (PDD), dementia with Lewy bodies (DLB), Lewy body variant of Alzheimer's disease (LBVAD), pure autonomic failure (PAF), multiple system atrophy (MSA), and neurodegeneration with brain iron accumulation type-1 (NBIA-I). [Continued on next page] WO 2018/178950 Al MIDEDIMOMMIDEFIEDMOMMINIHMEMOIMIE Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE